Latest Hotspot

The phase 2 clinical trial results of MoonLake's innovative nanobody treatment, Sonelokimab, have shown positive outcomes, effectively alleviating psoriasis

10 November 2023
3 min read

MoonLake Immunotherapeutics recently announced positive results from the global Phase 2 clinical trial, ARGO, assessing the efficacy and safety of its nanobody, sonelokimab, in patients with active psoriatic arthritis (PsA). The trial met its primary endpoint and all key secondary endpoints, with significant improvements in the Psoriasis Area and Severity Index of the patients after 12 weeks of treatment with sonelokimab.

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Sonelokimab is a new, innovative nanobody-based drug developed by MoonLake Immunotherapeutics, targeting IL-17A + IL-17F. It incorporates a nanobody that binds to serum albumin to extend its half-life and is composed of three VHH domains, with the third central domain binding to human serum albumin, which aids in further enrichment of sonelokimab at the inflammation edema sites. At present, clinical trials of sonelokimab are being conducted for psoriasis, hidradenitis suppurativa, and psoriatic arthritis.

In the ARGO trial, the primary endpoint was reached: the proportion of patients who achieved a 50% reduction in the American College of Rheumatology Disease Activity Score (ACR50) response at week 12 was significantly higher in patients treated with either 60 mg or 120 mg sonelokimab compared to those who received placebo. The drug discontinuation rate at week 12 was remarkably low (less than 4%) in the ARGO trial, similar to what was previously observed in trials of sonelokimab for psoriasis and hidradenitis suppurativa. Sonelokimab safety was consistent with previous study results, with no new safety signals observed. Specifically, the incidence of oral candidiasis in sonelokimab-treated patients was less than 2%, with no cases causing drug discontinuation. No cases of inflammatory bowel disease (IBD), major adverse cardiovascular events (MACE), or suicidal ideation and behavior (SI/B) were observed. Overall, sonelokimab continues to demonstrate robust safety, with no SI/B or liver enzyme elevation signals related to sonelokimab treatment identified so far in the entirety of the sonelokimab clinical program.

图形用户界面, 应用程序

描述已自动生成

According to information released by the synapse database as of November 9, 2023, there are eight drugs in development targeting IL-17A + IL-17F, encompassing 18 indications, 18 research institutions, 87 related clinical trials, and as many as 1721 patents. Cosentyx, a groundbreaking product from Novartis and the world's first monoclonal antibody targeting IL-17A, has seen its global sales consistently rise since its market debut, reaching $4.8 billion in 2022, consolidating its flagship status. With its positive clinical trial data, sonelokimab has the potential to carve out a niche in the arena of autoimmune diseases.

图形用户界面, 文本, 网站

描述已自动生成

Highly Efficient Treatment for Killing Drug-Resistant Bacteria: Bacteriophage Therapy
Advanced Tech.
6 min read
Highly Efficient Treatment for Killing Drug-Resistant Bacteria: Bacteriophage Therapy
10 November 2023
Challenging the pathogenicity of bacteria through Bacteriophage therapy could lead the way to improved antibiotic strategies.
Read →
New Generation Vaccine Adjuvant: TLR Agonists
New Generation Vaccine Adjuvant: TLR Agonists
10 November 2023
TLRs are innate immune receptors that are responsible, directly or indirectly, for detecting pathogen-associated molecular patterns (PAMPs) and responding to them through the activation of innate and adaptive immune pathways.
Read →
Molecular Templates has begun Phase 1 dosing of MT-8421, a distinct engineered toxin body targeting CTLA-4, for advanced solid tumor treatment
Latest Hotspot
3 min read
Molecular Templates has begun Phase 1 dosing of MT-8421, a distinct engineered toxin body targeting CTLA-4, for advanced solid tumor treatment
10 November 2023
Molecular Templates has commenced dosing in Phase 1 trial of MT-8421, a unique engineered toxin body targeting CTLA-4, for treating advanced solid tumors.
Read →
Decoding Voglibose: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
Drug Insights
4 min read
Decoding Voglibose: A Comprehensive Study of its R&D Trends and Mechanism on Drug Target
22 November 2023
This article summarized the latest R&D progress of Voglibose, the Mechanism of Action for Voglibose, and the drug target R&D trends for Voglibose.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.